Drug Approval | June 14, 2022
FDA accepts application for Merck’s Keytruda as adjuvant therapy for Stage IB-IIIA lung cancer
Acceptance based on results from the phase 3 KEYNOTE-091 trial
Acceptance based on results from the phase 3 KEYNOTE-091 trial
India’s first oncology laboratory for comprehensive Cancer Diagnostic services
Doubling of median overall survival seen in QuANTUM-First results presented at EHA Presidential Symposium
Tislelizumab is now approved in nine indications in China
Marinus has broadened inclusion criteria in the RAISE trial to allow for enrollment of patients previously treated with IV anesthesia.
During the research term, Olema will contribute funding to Aurigene to facilitate ongoing discovery efforts.
Healthcare is timely and personal – and its delivery should be too
Bayer now present in four of the largest biotechnology hubs in the United States
A big boost to healthcare efforts of Ayush through NARIP, CCRAS
TP-3654 is currently being evaluated in a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with intermediate or high-risk primary or secondary myelofibrosis.
Subscribe To Our Newsletter & Stay Updated
